Hi {{lead.First Name:default=edit me}},
Working in the greater Los Angeles area grants you access to same-day, fresh leukopaks from Sanguine’s first apheresis collection site.
You can leverage our 70,000+ research-ready participant network to obtain leukocyte-enriched apheresis products (leukopaks) from patients with confirmed disease or healthy donors. Customers tell us leukopaks are a game changer for their research by:
- Standardizing assay development and validations
- Reducing variability among donor PBMCs
- Improving the accuracy of process development parameters
How would up to 10 billion immune cells from a single donor delivered locally same-day from our LA site–plus clinical annotation, HLA typing, demographics, and test results–bolster your therapy development program?
Warm regards,
Brian Neman
CEO and Co-Founder
Sanguine Biosciences | Los Angeles